Healthcare & Life Sciences
Braeburn Pharmaceuticals
United States
alive
1
Investors
About
Braeburn Pharmaceuticals develops and commercializes treatments for opioid use disorder, including BRIXADI, an FDA-approved buprenorphine extended-release subcutaneous injection for moderate to severe opioid use disorder.
Explore Braeburn Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.